NTLA

Intellia Therapeutics Inc

Oct 13 • 04:00PM ET

23.76

-0.76 -3.10 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BEAM EDIT BNTX SGMO REPL CLLS FDMT PSTX ADPT

| Held by: ARKK ARKG XBI IWM VTI VB IWN VBK IBB SCHA

Index	RUT	P/E	-	EPS (ttm)	-4.69	Insider Own	5.39%	Shs Outstand	105.33M	Perf Week	15.68%
Market Cap	2.55B	Forward P/E	-	EPS next Y	-3.85	Insider Trans	1.47%	Shs Float	101.56M	Perf Month	108.06%
Enterprise Value	2.19B	PEG	-	EPS next Q	-1.01	Inst Own	87.75%	Short Float	29.28%	Perf Quarter	106.97%
Income	-480.19M	P/S	48.25	EPS this Y	21.08%	Inst Trans	-1.36%	Short Ratio	5.35	Perf Half Y	220.65%
Sales	52.86M	P/B	3.50	EPS next Y	6.96%	ROA	-45.94%	Short Interest	29.74M	Perf YTD	103.77%
Book/sh	6.79	P/C	5.55	EPS next 5Y	31.91%	ROE	-56.95%	52W High	26.99 -11.95%	Perf Year	34.62%
Cash/sh	4.28	P/FCF	-	EPS past 3/5Y	-11.59% -20.04%	ROIC	-60.72%	52W Low	5.90 302.71%	Perf 3Y	-62.10%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	20.53% 6.07%	Gross Margin	80.76%	Volatility	13.32% 10.08%	Perf 5Y	13.09%
Dividend TTM	-	EV/Sales	41.49	EPS Y/Y TTM	14.42%	Oper. Margin	-956.39%	ATR (14)	1.75	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.19	Sales Y/Y TTM	14.99%	Profit Margin	-908.48%	RSI (14)	74.21	Recom	1.54
Dividend Gr. 3/5Y	- -	Current Ratio	5.19	EPS Q/Q	35.60%	SMA20	27.08%	Beta	2.34	Target Price	34.04
Payout	-	Debt/Eq	0.14	Sales Q/Q	104.76%	SMA50	67.10%	Rel Volume	1.25	Prev Close	24.52
Employees	403	LT Debt/Eq	0.11	Earnings	Aug 07 BMO	SMA200	119.90%	Avg Volume	5.56M	Price	23.76
IPO	May 06, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.70% 19.85%	Trades		Volume	6,934,065	Change	-3.10%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$33
Apr-21-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$21
Mar-05-25	Initiated	H.C. Wainwright	Buy	$30
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral	$45 → $13
Feb-28-25	Downgrade	Goldman	Neutral → Sell	$9
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $11
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$67
Jan-24-23	Upgrade	Citigroup	Sell → Neutral	$48 → $39
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight	$84
Sep-21-22	Initiated	JP Morgan	Overweight	$85
Sep-01-22	Initiated	Citigroup	Sell	$50
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$54
Jun-16-22	Initiated	BofA Securities	Buy	$70
Apr-28-22	Initiated	Credit Suisse	Outperform	$100

Show Previous Ratings

Oct-12-25 09:45AM	4 Healthcare Stocks to Buy Now (Motley Fool)
Oct-09-25 09:23AM	Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock? (Zacks)
04:59AM	Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger 'Buy' (Insider Monkey)
Oct-08-25 12:00PM	Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know (Zacks) +19.72%
10:22AM	Stock Market Today: Stocks Tick Up Ahead of FOMC Minutes Release (TheStreet)
09:55AM	Loading…
09:55AM	Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know (Zacks)
09:40AM	Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-07-25 09:45AM	1 Stock Up by 63% This Year That Could Double, According to Wall Street (Motley Fool)
Oct-06-25 08:07AM	Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus (Zacks)
Oct-03-25 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-25 10:47AM	Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought (Motley Fool) +8.63%
Sep-25-25 01:57PM	Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug (Benzinga) -6.48%
09:52AM	Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
Sep-22-25 09:09AM	Take the Zacks Approach to Beat the Market: LendingTree, AutoZone, J&J in Focus (Zacks) +10.71%
07:30AM	Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
12:24PM	Loading…
Sep-19-25 12:24PM	NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up (Zacks)
09:20AM	Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength? (Zacks)
Sep-18-25 07:30AM	Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema (GlobeNewswire) +29.81%
Sep-11-25 03:45AM	Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190% (Motley Fool)
Sep-10-25 11:30AM	Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report? (Zacks)
Sep-02-25 03:46PM	Cathie Wood Pours $4 Million Into This High-Growth Biotech Stock (GuruFocus.com)
09:03AM	Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus (Zacks)
Aug-29-25 10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)
Aug-21-25 11:15AM	CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock (Zacks)
10:59AM	Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here? (Barchart)
Aug-12-25 11:40AM	Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? (Zacks)
Aug-11-25 07:43AM	Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus (Zacks)
Aug-08-25 11:19AM	Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus (Zacks) -5.85%
06:05AM	Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Market Research 2025 \| Key Players Include Intellia Therapeutics, Renowned for NTLA-2001 in Phase III Development, Leveraging CRISPR/Cas9 (GlobeNewswire)
03:55AM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
08:40AM	Loading…
Aug-07-25 08:40AM	Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Aug-01-25 07:30AM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-25 01:12PM	BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock (Zacks) -5.60%
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates (GlobeNewswire)
Jul-30-25 09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-28-25 08:41AM	Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus (Zacks)
Jul-15-25 04:27PM	Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (MarketBeat)
Jul-14-25 09:06AM	Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus (Zacks)
Jul-08-25 12:54PM	The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential. (Barchart) +8.49%
Jul-07-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:46AM	Intellia Gains 29.8% in a Month: How Should You Play the Stock? (Zacks)
Jul-03-25 09:18AM	Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data (Insider Monkey)
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
Jun-25-25 10:03AM	CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? (Zacks)
Jun-23-25 01:41AM	Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress (Insider Monkey)
Jun-18-25 09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
Jun-17-25 04:06PM	Verve Therapeutics Skyrockets Pulling Gene-Editing Stocks Higher On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily) +6.92%
01:32PM	Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential (Insider Monkey)
05:44AM	FDA clears CSLs swelling disease drug; Regeneron loses 23andMe auction (BioPharma Dive)
Jun-15-25 10:45AM	Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress (GlobeNewswire)
Jun-11-25 10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
Jun-05-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.73%
Jun-04-25 10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
09:55AM	How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% (Zacks)
08:55AM	Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? (Zacks)
May-30-25 10:20AM	NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks) -7.79%
05:56AM	Intellia stock dips following safety event in Phase III gene therapy trial (Clinical Trials Arena)
May-29-25 08:30PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -22.88%
08:18AM	Intellia stock tumbles on safety concerns (Investing.com)
07:16AM	Intellia filing spurs safety concerns over CRISPR drug (BioPharma Dive)
May-23-25 07:45AM	Analysts Think These Stocks Could More Than Double in Value (MarketBeat)
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-19-25 09:32AM	ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent (Zacks) +6.59%
May-18-25 07:25AM	Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting (GlobeNewswire)
May-16-25 10:51AM	Incyte Gets FDA Approval for Zynyz in New Cancer Indication (Zacks) +5.26%
May-15-25 09:55AM	Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High? (Zacks)
May-09-25 12:25PM	Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up (Zacks)
09:08AM	Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down (Zacks)
03:12AM	Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
May-08-25 05:27PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) +13.58%
12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks)
12:07PM	Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
08:45AM	Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-07-25 01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
12:09PM	ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down (Zacks)
11:57AM	Intellia Therapeutics Q1 2025 Earnings Preview (Seeking Alpha)
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
08:59AM	BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates (Zacks)
08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-06-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.10%
08:40AM	CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
May-05-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-01-25 10:01AM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline (Zacks)
09:30AM	Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average (Zacks)
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates (GlobeNewswire)
Apr-30-25 10:15AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool) +8.17%
Apr-29-25 09:55AM	Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet (Zacks)
Apr-23-25 09:50AM	Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation (PR Newswire)
Apr-22-25 05:30AM	Trumps FDA Sends a Bullish Signal to Biotech (The Wall Street Journal)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +9.54%
Apr-11-25 05:45AM	Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA (PR Newswire) +9.45%
Apr-09-25 09:42AM	Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple (Insider Monkey) +12.74%
Apr-04-25 01:42PM	Intellia Therapeutics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information NTLA (GlobeNewswire)
07:28AM	Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN (Clinical Trials Arena)
Apr-03-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.62%
12:40PM	IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility (Pharmaceutical Technology)
07:30AM	Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schultes Birgit C	EVP, Chief Scientific Officer	Oct 01 '25	Sale	17.38	31	539	105,184	Oct 03 05:13 PM
Dube Michael P	VP, Chief Accounting Officer	Oct 01 '25	Sale	17.38	1,871	32,518	55,266	Oct 03 05:13 PM
CHASE WILLIAM J	Director	Aug 20 '25	Buy	10.03	100,000	1,003,000	134,693	Aug 22 04:30 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jul 23 '25	Sale	14.02	7,462	104,617	106,062	Jul 25 04:05 PM
Clark Eliana	EVP, Chief Technical Officer	Jul 01 '25	Sale	9.82	1,022	10,036	95,369	Jul 03 04:11 PM
Dube Michael P	VP, Chief Accounting Officer	Jul 02 '25	Sale	9.95	2,503	24,905	57,137	Jul 03 04:07 PM
GOODMAN JESSE	Director	Jun 30 '25	Sale	9.56	1,547	14,789	25,906	Jul 02 05:50 PM
GOODMAN JESSE	Director	Jul 01 '25	Sale	9.23	1,547	14,279	24,359	Jul 02 05:50 PM
Bhanji Muna	Director	Apr 29 '25	Sale	8.50	265	2,252	19,203	May 01 04:24 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '25	Sale	8.99	679	6,104	95,369	Mar 04 04:43 PM
BASTA JAMES	EVP, General Counsel	Mar 04 '25	Sale	8.99	2,572	23,122	111,925	Mar 04 04:21 PM
Bhanji Muna	Director	Jan 29 '25	Sale	9.97	265	2,642	19,468	Jan 31 04:17 PM
Dube Michael P	VP, Chief Accounting Officer	Jan 03 '25	Sale	12.18	1,372	16,711	45,640	Jan 07 05:23 PM
BASTA JAMES	EVP, General Counsel	Jan 03 '25	Sale	12.18	7,074	86,161	74,497	Jan 07 05:22 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 03 '25	Sale	12.18	9,557	116,404	87,666	Jan 07 05:20 PM
Hicks Derek	EVP, Chief Business Officer	Jan 03 '25	Sale	12.18	6,502	79,194	59,878	Jan 07 05:20 PM
LEONARD JOHN M	President and CEO	Jan 03 '25	Sale	12.18	26,807	326,509	941,115	Jan 07 05:19 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 03 '25	Sale	12.18	8,966	109,206	77,388	Jan 07 05:16 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 03 '25	Sale	12.18	7,422	90,400	64,048	Jan 06 04:16 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 02 '25	Sale	12.03	556	6,689	71,470	Jan 06 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTLA

Intellia Therapeutics Inc

Upgrade your FINVIZ experience